Novavax (NVAX) Misses Q3 EPS, Revenue Beats; Guides to Low End
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Novavax Reports Third Quarter 2022 Financial Results and Operational Highlights
November 8, 2022 4:02 PM ESTAchieved total revenue for the third quarter of $735 million Delivered over 94 million doses of NVX-CoV2373 globally to dateAuthorized as a booster for adults in the U.S., E.U., and additional markets Authorized as a primary series for adolescents aged 12 17 years in U.S., EU, Japan, and additional markets Announced data about our prototype's broad immune response against circulating variants when used as a booster Initiated NVX-CoV2373 Phase 2b/3 study in children 6 months through 11 years of ageRefining full year 2022 total revenue... More
